CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 197 enrolled
Drug / intervention
Palbociclib + aromatase inhibitor +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05012644
NCT05012644N/ACompleted
CompareCT.gov

REAL-WORLD TUMOR RESPONSE OF PALBOCICLIB IN COMBINATION WITH AN AROMATASE INHIBITOR AS FIRST-LINE THERAPY IN PRE/PERIMENOPAUSAL WOMEN WITH METASTATIC BREAST CANCER

Pfizer·observational·Posted Aug 19, 2021·Updated Oct 8, 2024

In Brief

An observational study evaluating Palbociclib + aromatase inhibitor and Aromatase inhibitor for Metastatic Breast Cancer. Completed, enrolled 197 participants across 1 site.

Detailed Summary

This study aims to assess real-world tumor response in pre/perimenopausal HR+/HER2- metastatic breast cancer (MBC) patients initiating palbociclib + aromatase inhibitor (AI) or AI alone as first-line therapy during the period on or after 01 January 2010 to on or before 30 June 2020. Data will be obtained from structured data fields within an electronic health record (EHR) database and will be supplemented by additional unstructured data collected through a targeted chart review.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedAug 19, 2021
Enrollment StartJul 16, 2021
Primary CompletionDec 9, 2021
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 4.9 years ago

Interventions

Palbociclib + aromatase inhibitordrug

Palbociclib + aromatase inhibitor

Aromatase inhibitordrug

Aromatase inhibitor